Ruxolitinib for essential thrombocythemia refractory to or intolerant of hydroxyurea: long-term phase 2 study results

Srdan Verstovsek, Francesco Passamonti, Alessandro Rambaldi, Giovanni Barosi, Elisa Rumi, Elisabetta Gattoni, Lisa Pieri, Huiling Zhen, Muriel Granier, Albert Assad, Mario Cazzola, Hagop M. Kantarjian, Tiziano Barbui, Alessandro M. Vannucchi

Research output: Contribution to journalLetter

Original languageEnglish
Pages (from-to)1768-1771
Number of pages4
JournalBlood
Volume130
Issue number15
DOIs
Publication statusPublished - Oct 12 2017

ASJC Scopus subject areas

  • Biochemistry
  • Immunology
  • Hematology
  • Cell Biology

Cite this

Verstovsek, S., Passamonti, F., Rambaldi, A., Barosi, G., Rumi, E., Gattoni, E., Pieri, L., Zhen, H., Granier, M., Assad, A., Cazzola, M., Kantarjian, H. M., Barbui, T., & Vannucchi, A. M. (2017). Ruxolitinib for essential thrombocythemia refractory to or intolerant of hydroxyurea: long-term phase 2 study results. Blood, 130(15), 1768-1771. https://doi.org/10.1182/blood-2017-02-765032